Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Werewolf Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 45 | 42 | −3 |
| Shares | 19.8M | 19.0M | −750.3K (−3.8%) |
| Value | $344.3M | $326.2M | −$18.1M (−5.3%) |
New holders (2)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Russell Investments Group, Ltd. | 125,873 | $2.16M | 0.00% |
| Levin Capital Strategies, L.P. | 15,000 | $257.0K | 0.03% |
Sold out (5)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Goldman Sachs Group Inc | 37,435 | $653.0K |
| Aristides Capital LLC | 25,585 | $446.0K |
| Arena Capital Advisors, LLC- CA | 14,958 | $261.0K |
| Schonfeld Strategic Advisors LLC | 11,300 | $197.0K |
| Capstone Investment Advisors, LLC | 10,000 | $174.0K |